[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"doxycycline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:doxycycline":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652070","phase-2-multicentre-study-evaluating-the-efficacy-of-a-7-day-course-of-doxycycline-for-the-treatment-of-asymptomatic-anal-lymphogranuloma-venereum-100652070",false,"NCT07767422","Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum.","Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum","SHORT-LGV","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Male sex at birth\n* LGV-positive result on anal specimen using Nucleic Acid Amplification Test at screening\n* Having taken at least doxycycline for two days (i.e 400 mg of doxycycline)\n* Not having taken more than 7 days of doxycycline 200 mg per day\n* No more than 12 days between the date of sampling and date of inclusion\n* No anorectal symptoms\n* Individual available for participation and follow-up during the four weeks required for the study\n* Affiliate or beneficiary of a social security scheme\n* Free written informed consent signed by the participant or by a legal representative (in the event of the participant's inability to consent) and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Individual with anorectal symptoms\n* Antibiotic treatment with antichlamydial activity (fluoroquinolones, macrolides-lincosamides-streptogramins, tetracyclines and rifampicin) within 28 days before the screening visit\n* Use of doxycycline post-exposure prophylaxis (Doxy-PEP)\n* Participation in another study\n* Individual under a measure of legal protection measure (safeguard of justice, guardianship or curatorship) or unable to consent\n* Refusal to participate in the study\n* Mental state rendering the person giving consent incapable of understanding the entirety of the trial\n* Participant detained by judicial or administrative decision.\n* Individual receiving an anticoagulant therapy\n* Individual with a history of known hypersensitivity to doxycycline or any other antibiotic of the tetracycline family or allergy to any of the excipients (Hydrogenated castor oil, povidone, anhydrous colloidal silica, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch (type A)).\n* Individual treated with retinoids by general route.\n* Individual receiving 10,000 IU of vitamin A per day or more\n* Individual being a relative of the investigator or a relative of someone from the team directly involved in the trial, including assistant doctors, pharmacists, nurses, and trial coordinators","MALE","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by the L genotypes of C. trachomatis. Proctitis is the main clinical manifestation of infection in the current LGV epidemic. However, recent European studies reported that about 25% of the anal LGV infections are asymptomatic. In France, asymptomatic anal LGV increased from 36.1% (44\u002F124) in 2020 to 52.4% (66\u002F126) in 2022. LGV testing is recommended on all C. trachomatis-positive anorectal specimens because therapy of extended duration is required. Patients with anal C. trachomatis infection should be treated initially with 7-day course of doxycycline (200 mg per day orally) while awaiting the results of LGV testing. Treatment should be extended to 21 days in cases of LGV according to current European and USA guidelines for LGV treatment. This regimen is indicated for symptomatic and asymptomatic anorectal LGV, with a 98.5% treatment efficacy. However, there is no obvious biological basis for prolonged treatment of asymptomatic LGV. Three recent retrospective studies showed that a 7-day course of doxycycline was effective for the treatment of asymptomatic LGV, with microbial cure ranging from 97% (38\u002F39) to 100% (54\u002F54). The objective of this study is to evaluate the efficacy (microbiological cure rate) of a 7-day course of doxycycline 200 mg daily orally for the treatment of asymptomatic anal LGV infection, four weeks after treatment initiation.",[27,28,29],"Lymphogranuloma Venereum","no Anorectal Symptoms","Doxycycline",[31,32,33,34],"Lymphogranuloma venereum","Chlamydia trachomatis","asymptomatic","doxycycline","NOT_YET_RECRUITING","2026-08-11",{"date":38,"type":39},"2026-08-17","ACTUAL",{"date":41,"type":21},"2026-09",{"date":43,"type":21},"2027-11",{"name":45,"class":46},"University Hospital, Bordeaux","OTHER",14,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100575884","sti-prophylaxis-and-emergence-of-antimicrobial-resistance-100575884","NCT06778083","STI Prophylaxis and Emergence of Antimicrobial Resistance","SPEAR","Inclusion Criteria:\n\n* Aged ≥ 18 years.\n* Identifies as a man (cis or trans).\n* Has sex with men.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Use of an antibiotic other than doxycycline in the 3 months prior to enrolment\n* Currently being treated for an STI with doxycycline\n* Use of doxycycline within the prior 3 months for an indication other than STI treatment or STI prevention.",true,{"count":57,"type":21},108,"OBSERVATIONAL","The goal of this observational study is to understand the risk of antibiotic resistance and changes in the human microbiome (bacteria that live inside and on us), if people use antibiotics to prevent sexually transmitted infections (STI prophylaxis, doxycycline post-exposure prophylaxis, or 'doxyPEP'). The study will assess how easy and acceptable it is to find antibiotic resistance and microbiome changes in the throats and guts of men-who-have-sex-with-men (MSM) who use STI prophylaxis.\n\nThe study will recruit 108 MSM who are using and not using STI prophylaxis. Participants will visit the clinic every 6 months. At each visit, they will provide a throat swab and stool sample, and complete a questionnaire. DNA of the bacteria from the samples will be analysed to identify the bacteria and look for antibiotic resistance.",[61,62,63,64,29],"Sexually Transmitted Infection (STI) Prevention","Antibiotic Prophylaxis","Antibiotic Resistance, Bacterial","Microbiome",[66,67,29,68,69,70,64,71],"DoxyPEP","STI Prophylaxis","STI Prevention","Antimicrobial Resistance","Antibiotic Resistance","Men-who-have-sex-with-men","RECRUITING","2025-03-26",{"date":75,"type":39},"2025-03-27",{"date":77,"type":39},"2025-02-10",{"date":79,"type":21},"2027-04-30",{"name":81,"class":46},"University College, London",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100516669","pharmacokinetic-characterization-of-a-single-200-mg-dose-of-doxycycline-in-post-exposure-prophylaxis-pep-of-sexually-transmitted-infections-in-different-biological-compartments-100516669","NCT06007534","Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments","Caractérisation de la pharmacocinétique d'Une Dose Unique de 200 mg de Doxycycline en Prophylaxie Post-exposition (PEP) Des Infections Sexuellement Transmissibles Dans différents Compartiments Biologiques","DOXY-PK","Inclusion Criteria:\n\n* Adult male patient\n* Men who have Sex with Men (MSM) on PrEP or HIV-infected patients\n* Patients who have not taken doxycycline for at least 3 months\n* No symptoms of bacterial STI infection (chlamydia, gonorrhea, Mycoplasma genitalium or syphilis).\n* Documented history of bacterial STI infection within the past 12 months\n* Having had a risky intercourse within 24 hours and at the latest within 72 hours and for which a prescription of doxycycline in a single dose of 200 mg has been made within the framework of his usual follow-up.\n* Free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out within the framework of the study (article L1122-1-1 of the Public Health Code).\n* Person affiliated or benefiting from a social security system (article L1121-11 of the Public Health Code)\n\nExclusion Criteria:\n\n* Systemic treatment with retinoids (Acnetrait®, Procuta®, Curacné®, Contracné®, ....).\n* Treatment with enzyme-inducing anticonvulsants (carbamazepine, phenobarbital, phenytoin, etc.).\n* Known allergy to antibiotics of the tetracycline family.\n* Known allergy to one of the components of doxycycline tablets.\n* Documented esophageal injury\n* Ongoing treatment with doxycycline at the time of inclusion.\n* Person participating in another research study with an exclusion period still in progress at inclusion.\n* Persons under guardianship, conservatorship, or deprived of liberty by judicial or administrative decision.\n* Patients on State Medical Aid","100 Years",{"count":93,"type":21},25,[95],"NA","Post-exposure prophylaxis (PEP) using doxycycline 200 mg within 24 hours of unprotected sexual intercourse to prevent sexually transmitted infections has demonstrated a reduction in the incidence of chlamydial and syphilis infections and syphilis infection by 70% and 73% in men who have sex with men (MSM) undergoing pre-exposure prophylaxis prophylaxis (PrEP) for HIV. Other studies are underway or in development on doxycycline prophylaxis for bacterial STIs, which are particularly common in this population. Monitoring adherence to PEP is of great interest in guaranteeing the effectiveness of this strategy and to be able to assess the uptake of PEP among PrEP users. Among the many methods for assessing adherence, measuring drug concentrations is a more accurate measure of adherence than self-reporting.\n\nThe therapeutic monitoring of doxycycline and the assessment of adherence have been described using plasma and hair samples, allowing estimation of intake over the last 3-4 days and 4 months, respectively. Nevertheless, these biological matrices present several limitations for application in clinical practice: reflecting the duration of exposure should be more in line with the frequency of visits (2 months), and the collection of hair samples may be difficult due to refusal or short hair. On the other hand, interpretation of the hair assay is limited by the degradation of doxycycline in this matrix, which could lead to underestimation of drug intake. By Therefore, new biological matrices are needed for more accurate assessment of doxycycline adherence in post-exposure prevention monitoring.\n\nThe objective is to evaluate the pharmacokinetics of doxycycline in plasma, whole blood, dried blood spots (DBS), urine and hair after a single dose of doxycycline in men using oral doxycycline for post-exposure prophylaxis of sexually transmitted infections (syphilis or Chlamydia trachomatis) and having sex with men.",[98,99,29],"Post-exposure Prophylaxis","Sexually Transmitted Diseases","2024-09-13",{"date":102,"type":39},"2024-09-19",{"date":104,"type":39},"2023-10-25",{"date":106,"type":21},"2025-04-25",{"name":108,"class":46},"Assistance Publique - Hôpitaux de Paris",2]